A Phase 1/2 Open-Label, Single Ascending Dose Trial of a

Project: Research project

Description

A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adenoassociated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults with Hemophilia B
StatusFinished
Effective start/end date5/30/125/30/17

Funding

  • ASKLEPIOS Biopharmaceutical, Inc.

Fingerprint

Hemophilia B
Factor IX
Genetic Therapy
Viruses
Serogroup